Document is current

Article History

Received: 1 October 2024

Accepted: 2 October 2024

First Online: 29 October 2024

Disclosures

: Giorgos Karakousis has received research funding from Merck; was the Principal Investigator (PI) of an investigator-initiated trial on neoadjuvant PD-1 therapy for clinical stage II B/C melanoma from 2019 to the present (research monies to support the trial and studies are paid to the institution); and is a member of the Advisory Boards for Merck and Bristol Myers Squibb (no direct relationships to the project). Tina J. Hieken has received research funding from Genentech and SkylineDx (current research funding is paid to the institution). Genevieve Boland is a consultant and advisor, and has received research funding. She has been a speaker for Novartis and Takeda Oncology (2019); a consultant for NW Biotherapeutics (2020), Merck (2021), InterVenn Biosciences (2021), and Ankyra Therapeutics (2021); a member of the Advisory Boards of Iovance (2021, 2023) and Merck (2021, 2022, 2023); a member of the Scientific Advisory Board and Steering Committee for Nektar Therapeutics (2020); a member of the Surgical Advisory Board for Novartis (2020); a member of the Scientific Advisory Board for Ankyra Therapeutics (2021, 2022, 2023) and Moderna (June 2024); had sponsored research agreements for Olink Proteomics, Palleon Pharmaceuticals, and InterVenn Biosciences (2021); and held stock in Ankyra Therapeutics (2021). Marc Moncrieff is an advisor and has received honoraria, travel expenses, and research funding. He was the recipient of a grant from the UK National Institute for Health and Care Research (NIHR, grant 19/102: 130886); received an honorarium and travel expenses from Novartis, Canada, in December 2019; and received an honorarium from Amgen to attend an advisory panel session in October 2019. Edmund K. Bartlett received honoraria from Excite International in 2021; received research funding and institutional research support from Skyline Dx (Rotterdam, The Netherlands, and San Diego, CA, USA) pertaining to the Merlin Assay that is ongoing; and institutional research support from Qbiotics Group. Tawnya Bowles received research funding from Genentech (2019 to the present), and was PI for a melanoma clinical research study, PI for a clinical research study conducted by Amgen (2018 to the present), PI for a clinical research study conducted by Replimune (2019 to the present), and PI for a clinical research study conducted by Natera (2020 to the present); however, she does not receive any direct funds from these sources. Cristina O’Donoghue, Keith A. Delman, Sandra Wong, and Richard L. White Jr have no conflicts of interest to declare that may be relevant to the contents of this article. Authors and reviewers have disclosed potential conflicts of interest consistent with SSO policy. Disclosures are also listed in the Appendix.

: Comments on this document may be sent to the SSO for consideration in future iterations of the work.